Medication info

5% Dextrose Kit Injection

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Glucose›5g / 100mL
Manufacturer / importer
UK Chemipham Co., Ltd.
Appearance
A kit injection composed of a capsule part for powder injection and a colorless, transparent polypropylene container containing the solvent.
Packaging
100 milliliters/kit [x 10], 110 milliliters/kit [x 10], 250 milliliters/kit [x 10]
Approval status
Active

MFDS item code 200503698 · Notified 2005.01.28 · Insurance code 672900021

Summary

Main use
Dissolution and dilution of injectable drugs; treatment of dehydration through fluid replacement
Who receives it
Adults
Adult administration
○ Adults: Administer 500∼1000 mL intravenously per dose. ○ The intravenous infusion rate should not exceed 0.5 g/kg per hour as glucose. ○ Use an appropriate amount to dissolve and dilute injectable products. Adjust the dose appropriately according to age and symptoms.

Ingredients

Manufacturer
UK Chemipham Co., Ltd.

Efficacy & effects

Dissolution and dilution of injectable drugs; treatment of dehydration through fluid replacement

  • Dehydration
  • fluid deficiency
View approved original text

This medication is used to replenish fluids in cases of dehydration, especially when the body is deficient in water. It is also used as a solvent for the dissolution and dilution of injectable medications. Thus, it helps maintain the body's fluid balance and facilitates the administration of necessary injectable medications.

How it is given

Adult administration

○ Adults: Administer 500∼1000 mL intravenously per dose. ○ The intravenous infusion rate should not exceed 0.5 g/kg per hour as glucose. ○ Use an appropriate amount to dissolve and dilute injectable products. Adjust the dose appropriately according to age and symptoms.

Precautions

This medication contains dextrose for injection and requires caution during intravenous administration as it may increase the consumption of vitamin B1, potentially leading to severe deficiency. This medication should not be administered to specific patients, such as those with storage dehydration, fluid overload, hyperglycemia, acidosis, hypokalemia, hyperosmolar coma, and patients with glucose intolerance. Additionally, it is safe not to use this medication in patients with anuria, hepatic coma, patients with hypersensitivity to this medication, and patients with spinal or intracranial hemorrhage. It should be administered cautiously in patients with tendencies towards potassium, phosphate, and magnesium deficiency or in patients with hyponatremia, diabetes insipidus, renal failure, and heart failure, who require careful management. This medication can cause side effects such as electrolyte imbalance, fluid overload, and pulmonary edema when administered in large doses, so it should be used with careful adjustments to the dose and rate. Furthermore, in patients who have difficulty controlling blood sugar levels, hyperglycemia or renal damage may occur, requiring periodic monitoring of blood glucose and electrolyte levels. During pregnancy, safety for the fetus has not been established and should only be used when the potential benefits outweigh the risks, and care should be taken regarding blood sugar changes in the mother and newborn during administration. Newborns, especially preterm or low birth weight infants, are at higher risk for hypoglycemia or hyperglycemia and require close monitoring of blood sugar status. Elderly patients may have diminished physiological functions, so care should be exercised in their administration. In cases of excessive dosing, hyperglycemia may develop, necessitating insulin treatment. This medication is not recommended for administration by subcutaneous injection; it should be used immediately after opening, and any unused solution should be discarded. To prevent infection at the injection site, cleanliness should be maintained, and it is advisable to warm the solution to body temperature before use. When used in conjunction with other medications, potential chemical interactions and adverse reactions should be adequately considered and carefully observed. When used for hydration in dehydrated patients, it should be administered slowly, and appropriate procedures should be followed for the dissolution process. Finally, to reduce the risk of air embolism, continuous connection use should be avoided.

Side effects

  • Electrolyte loss
  • elevated bilirubin levels
  • elevated lactate levels
  • hypokalemia
  • hyperosmolar coma
  • acidosis
  • dehydration
  • hyperosmolarity
  • polyuria
  • fluid or solute overload
Show 11 more
  • fluid-electrolyte imbalance
  • congestion
  • pulmonary edema
  • hyperglycemia
  • renal loss
  • fever
  • phlebitis
  • thrombosis
  • extravasation of blood
  • injection site pain
  • uremia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air ingress and should be kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

A kit injection composed of a capsule part for powder injection and a colorless, transparent polypropylene container containing the solvent.

Package unit

100 milliliters/kit [x 10], 110 milliliters/kit [x 10], 250 milliliters/kit [x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.